Reported Saturday, Lilly's Triple Agonist Retatrutide Achieves 28.3% Weight Loss And 60.6% Sleep Apnea Reduction In Phase 3 TRIUMPH-1 Trial At 80 Weeks

Loading news article.

Reported Saturday, Lilly's Triple Agonist Retatrutide Achieves 28.3% Weight Loss And 60.6% Sleep Apnea Reduction In Phase 3 TRIUMPH-1 Trial At 80 Weeks | WAPE

Reported Saturday, Lilly's Triple Agonist Retatrutide Achieves 28.3% Weight Loss And 60.6% Sleep Apnea Reduction In Phase 3 TRIUMPH-1 Trial At 80 Weeks

Article summary

Related companies

Comments —